FLT3 and acute myeloid leukemia: We suggest that a thorough molecular characterisation of FLT3‐ITDs in AML patients undergoing FLT3‐targeting therapy could provide novel biological insight that could ultimately increase predictive and therapeutic precision in FLT3‐ITD mutated AML.